JP2007511219A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511219A5 JP2007511219A5 JP2006539071A JP2006539071A JP2007511219A5 JP 2007511219 A5 JP2007511219 A5 JP 2007511219A5 JP 2006539071 A JP2006539071 A JP 2006539071A JP 2006539071 A JP2006539071 A JP 2006539071A JP 2007511219 A5 JP2007511219 A5 JP 2007511219A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- cxcr4
- sdf
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 86
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 32
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 23
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 238000002054 transplantation Methods 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 230000007115 recruitment Effects 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 12
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 12
- 230000011664 signaling Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 230000000925 erythroid effect Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000000586 desensitisation Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 210000002960 bfu-e Anatomy 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- -1 Mip-1α Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000699667 Mus spretus Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108091008044 human SRC Proteins 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-N tetramethylazanium;hydrochloride Chemical compound Cl.C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15886803A IL158868A0 (en) | 2003-11-13 | 2003-11-13 | Methods of generating and using stem cells enriched with immature primitive progenitor |
| PCT/IL2004/001018 WO2005047494A2 (en) | 2003-11-13 | 2004-11-08 | Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012032163A Division JP5547221B2 (ja) | 2003-11-13 | 2012-02-16 | 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511219A JP2007511219A (ja) | 2007-05-10 |
| JP2007511219A5 true JP2007511219A5 (enExample) | 2011-01-27 |
Family
ID=34044273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539071A Pending JP2007511219A (ja) | 2003-11-13 | 2004-11-08 | 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 |
| JP2012032163A Expired - Fee Related JP5547221B2 (ja) | 2003-11-13 | 2012-02-16 | 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012032163A Expired - Fee Related JP5547221B2 (ja) | 2003-11-13 | 2012-02-16 | 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080025957A1 (enExample) |
| EP (1) | EP1682653B1 (enExample) |
| JP (2) | JP2007511219A (enExample) |
| AU (1) | AU2004288879B2 (enExample) |
| CA (1) | CA2545409A1 (enExample) |
| ES (1) | ES2534724T3 (enExample) |
| IL (2) | IL158868A0 (enExample) |
| NO (1) | NO335515B1 (enExample) |
| WO (1) | WO2005047494A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271639A1 (en) * | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
| CN101495623B (zh) | 2006-03-24 | 2013-09-11 | 儿童医疗中心有限公司 | 调节造血干细胞生长的方法 |
| EP2679221B1 (en) | 2006-10-20 | 2020-09-23 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| CA2682469A1 (en) | 2007-03-30 | 2008-10-09 | The Cleveland Clinic Foundation | Method of treating ischemic disorders |
| US8198083B1 (en) | 2007-10-31 | 2012-06-12 | William Gunter Loudon | Organotypic slices of the central nervous system |
| WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| US20120283315A1 (en) | 2009-08-28 | 2012-11-08 | Penn Marc S | Sdf-1 delivery for treating ischemic tissue |
| US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
| MX359398B (es) | 2011-09-30 | 2018-09-27 | Bluebird Bio Inc | Compuestos para transduccion viral mejorada. |
| WO2013082243A1 (en) * | 2011-12-02 | 2013-06-06 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
| EP3413896B1 (en) | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3014078A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| GB201807944D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Compositions and methods for haematopoietic stem cell transplantation |
| WO2022054999A1 (ko) * | 2020-09-14 | 2022-03-17 | 주식회사 제너로스 | 생착능이 증가된 줄기세포의 제조 방법 |
| WO2023010068A2 (en) * | 2021-07-28 | 2023-02-02 | Cartesian Therapeutics, Inc. | Multiprotein-engineered cells secreting a multispecific antibody |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4879111A (en) * | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4965195A (en) * | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| EP0386476B1 (en) * | 1989-02-06 | 1994-07-13 | Mitsubishi Petrochemical Co., Ltd. | Process for producing L-alanine |
| US6326198B1 (en) * | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5837539A (en) * | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| WO1996037208A1 (en) * | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| US6090622A (en) * | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| US6511958B1 (en) * | 1997-08-14 | 2003-01-28 | Sulzer Biologics, Inc. | Compositions for regeneration and repair of cartilage lesions |
| IL135068A (en) * | 1997-09-29 | 2004-03-28 | Point Therapeutics Inc | Stimulation of hematopoietic cells in vitro |
| US6132708A (en) * | 1997-10-10 | 2000-10-17 | Oregon Health Sciences University | Liver regeneration using pancreas cells |
| US6248587B1 (en) * | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
| EP1061949B1 (en) * | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| US6383481B1 (en) * | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| US6184035B1 (en) * | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
| US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
| US6436704B1 (en) * | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
| DK2371361T3 (da) * | 2001-07-31 | 2019-08-19 | Genzyme Corp | Fremgangsmåder til mobilisering af progenitor-/stamceller |
| AU2002347563A1 (en) * | 2001-12-06 | 2003-06-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| IL146970A0 (en) * | 2001-12-06 | 2002-08-14 | Yeda Res & Dev | Migration of haematopoietic stem cells and progenitor cells to the liver |
-
2003
- 2003-11-13 IL IL15886803A patent/IL158868A0/xx unknown
-
2004
- 2004-11-08 US US10/578,291 patent/US20080025957A1/en not_active Abandoned
- 2004-11-08 WO PCT/IL2004/001018 patent/WO2005047494A2/en not_active Ceased
- 2004-11-08 AU AU2004288879A patent/AU2004288879B2/en not_active Ceased
- 2004-11-08 CA CA002545409A patent/CA2545409A1/en not_active Abandoned
- 2004-11-08 JP JP2006539071A patent/JP2007511219A/ja active Pending
- 2004-11-08 EP EP04799327.4A patent/EP1682653B1/en not_active Expired - Lifetime
- 2004-11-08 ES ES04799327.4T patent/ES2534724T3/es not_active Expired - Lifetime
-
2006
- 2006-05-04 IL IL175430A patent/IL175430A/en not_active IP Right Cessation
- 2006-06-12 NO NO20062709A patent/NO335515B1/no not_active IP Right Cessation
-
2011
- 2011-02-21 US US13/031,466 patent/US8367057B2/en not_active Expired - Fee Related
-
2012
- 2012-02-16 JP JP2012032163A patent/JP5547221B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511219A5 (enExample) | ||
| JP4517005B2 (ja) | ＣＤ４９ｃおよびＣＤ９０を共発現する細胞集団 | |
| CN102626517B (zh) | 调节造血干细胞生长的方法 | |
| US5874301A (en) | Embryonic cell populations and methods to isolate such populations | |
| CN1228443C (zh) | 人胚胎干细胞的造血分化 | |
| Yamaguchi et al. | Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cells expansion | |
| JP2020505934A5 (enExample) | ||
| Urbinati et al. | Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease | |
| WO2005030040A2 (en) | Hematopoietic stem cell identification and isolation | |
| WO2020158924A1 (ja) | 母児間免疫寛容を誘導する方法 | |
| US20020160512A1 (en) | Ex vivo expansion of mammalian hematopoietic stem cells | |
| JP4834291B2 (ja) | Ｓｔａｔ３活性化幹細胞 | |
| JP6861405B2 (ja) | 造血系細胞の作製方法 | |
| CN114209814A (zh) | Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途 | |
| JP2014227418A (ja) | Ｎｋ細胞の調製方法 | |
| US20230383257A1 (en) | Production of megakaryocytes and platelets in a co-culture system | |
| US20070124826A1 (en) | Method of differentiation from embryo-stem cell of primate to hematogenous cell | |
| CN1926234A (zh) | 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途 | |
| US20100209396A1 (en) | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells | |
| CA2113555A1 (en) | Yolk sac stem cells | |
| WO2003089592A2 (en) | Enhancement of hematopoietic stem cell survival | |
| Winterhalter | CRISPR/Cas9 based HLA reduction of T cells for universal T cell therapy | |
| WO2023176709A1 (ja) | 造血幹細胞移植における移植前処理を受けた患者を処置する方法および当該方法に用いるための組成物 | |
| WO2006085482A1 (ja) | 造血幹細胞の自己複製因子及び増幅方法 | |
| JPWO1999003980A1 (ja) | Ａｇｍ領域由来ストローマ細胞 |